Arena Pharmaceuticals initiates patient screening for phase 1 clinical trial of APD916
Links shared publicly online about this topic.
- 1,289total visits
Arena Pharmaceuticals initiates patient screening for phase 1 clinical trial of APD916
Arena Pharmaceuticals, Inc. announced today the initiation of patient screening in a Phase 1 clinical trial of APD916, a novel oral drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy and cataplexy.
View full resource at news-medical.net
Tags: Sleep Disorder, Narcolepsy, Drug, Pharma, Phase 1 Clinical Trial, Clinical Trial
Most Recently Shared on March 25, 2010 at 2:02 pm By:
Arena Pharmaceuticals initiates patient screening for phase 1 clinical trial of APD916: Arena Pharmaceuticals, Inc... http://bit.ly/cIdeCN
Arena Pharmaceuticals Announces Initiation Of Phase 1 Clinical Trial Of APD916 For Narcolepsy And Cataplexy
medicalnewstoday.com — “Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced the initiation of patient screening in a Phase 1 clinical trial of APD916, a novel oral drug candidate discovered by Arena that targets the his” View full resource at medicalnewstoday.com
Most Recently Shared on March 25, 2010 at 3:13 pm By:
Arena Pharmaceuticals Announces Initiation Of Phase 1 Clinical Trial Of APD916 For Narcolepsy And Cataplexy http://mnt.to/3zqP #epilepsy
Advertisement
